Methodology
The Institute is actively involved in the development of methods for evidence syntheses, i.e., methods for survival time endpoints (time-to-event outcomes), the further development of prognostic reviews within Cochrane, and the further development of the living evidence approach. Employees are members of the GRADE Working Group, the Cochrane Prognosis Methods Group, and the Living Evidence Network.
Working Group
- Mario Czenar
- Marius Goldkuhle
- Caroline Hirsch
- Nina Kreuzberger
Ongoing projects
Complex systematic reviews with a methodological focus
- Prognostic factors for predicting treatment success and safety of chimeric antigen receptor (CAR) T-cell therapy in adult aggressive large B-cell lymphomas (PREDICART; BMBF funding number 01KG2204)
Completed projects
Complex systematic reviews with a methodological focus
- Prognostic models for chronic lymphocytic leukemia (CLL): an exemplary review and meta-analysis (BMBF funding number 01KG1711)
- Interim PET for prognosis assessment in adults with Hodgkin lymphoma: an exemplary review of prognostic factors (BMBF funding code 01KG1709)
Further projects
- Assessment of the current state of consideration of the specifics of time-to-event analyses in meta-analyses: Re-analysis of systematic reviews and implementation of guidelines (META-TTE; DFG funding code SK 146/2-1)
- Scoping review and methodological challenges for living systematic reviews conducted during COVID-19 (within CEOSYS, BMBF funding code 01KX2021)